https://www.ibcomms.agency/releases24/cellprothera-signs-mou-with-shonan-kamakura-general-hospital-for-use-of-stemxpand%C2%AE-in-japanese-stem-cell-clinical-trial%C2%A0 2025-01-07 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-presents-data-on-automated-red-blood-cell-exchange-to-treat-sickle-cell-disease-at-the-american-society-of-hematology%C2%A0 2025-01-07 https://www.ibcomms.agency/releases24/blood-and-cells-advocacy-roster-(bcar)-launches-to-provide-joint-voice-for-the-blood-industry 2025-01-07 https://www.ibcomms.agency/releases24/leriglitazone-has-met-the-primary-endpoint-in-nexus%2C-the-pivotal-trial-for-pediatric-patients-with-cerebral-adrenoleukodystrophy 2024-12-11 https://www.ibcomms.agency/releases24/likarda-partners-with-vitalte-to-develop-extended-release-injectable-hormone-therapies%C2%A0 2024-12-11 https://www.ibcomms.agency/releases24/vivebiotech-secures-growth-investment-from-ampersand-capital-partners-to-expand-lentiviral-vector-development-and-manufacturing-capabilities 2024-12-11 https://www.ibcomms.agency/releases24/multi-center-superiority-clinical-trial%2C-supported-by-terumo-blood-and-cell-technologies%2C-aims-to-significantly-reduce-complications-from-acute-chest-syndrome-in-adult-sickle-cell-disease-patients 2024-12-11 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-advances-the-adoption-of-automated-manufacturing-to-bring-novel-cell-and-gene-therapies-to-more-latin-american-patients- 2024-12-11 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-avanza-en-la-adopci%C3%B3n-de-la-fabricaci%C3%B3n-automatizada-para-llevar-nuevas-terapias-celulares-y-g%C3%A9nicas-a-m%C3%A1s-pacientes-de-am%C3%A9rica-latina- 2024-12-11 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-unlocks-new-chapter-of-localization-in-china-to-facilitate-blood-and-cell-treatment-options-for-patients 2024-12-11 https://www.ibcomms.agency/releases24/sekisui-completes-%C2%A315.7-million-expansion-in-cgmp-biopharma-cdmo-capacity 2024-12-11 https://www.ibcomms.agency/releases24/advanced-therapies-week-2025-agenda-reveals-provocative-sessions-on-biotech-investment%2C-regulatory-shifts%2C-and-patient-centered-innovation- 2024-12-11 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-merges-therapeutics-units-to-enhance-patient-care-across-treatment-journey 2024-12-11 https://www.ibcomms.agency/releases24/reithera-partners-with-rwanda-and-sabin-vaccine-institute-in-joint-effort-to-combat-marburg-virus-outbreak 2024-12-11 https://www.ibcomms.agency/releases24/reithera-delivers-drug-substance-%26-drug-product-in-aavantgarde's-groundbreaking-large-gene-therapy-trial-for-usher-syndrome-type-1b- 2024-12-11 https://www.ibcomms.agency/releases24/green-elephant-biotech-gmbh-expands-cellscrew%C2%AE-product-line-to-enable-sustainable-commercial-cell-and-gene-therapy-scale-up 2024-12-11 https://www.ibcomms.agency/releases24/reithera-manufactures-vectors-for-eg-427's-phase-1b%2F2a-gene-therapy-clinical-trial-for-neurological-bladder-disorder 2024-12-11 https://www.ibcomms.agency/releases24/reithera-announces-multiple-presentations-at-2024-esgct-annual-congress-showing-the-potential-of-the-production-of-genetic-vaccines 2024-12-11 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-kicks-off-u.s.-launch-of-reveos-automated-blood-processing-system-with-blood-centers-of-america 2024-12-11 https://www.ibcomms.agency/releases24/reithera-supported-the-sabin-vaccine-institute-and-global-health-efforts-by-manufacturing-and-shipping-marburg-vaccine-doses-to-rwanda-in-collaboration-with-the-sabin-vaccine-institute 2024-12-11 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-and-sanquin-to-automate-whole-blood-processing-across-the-netherlands- 2024-12-11 https://www.ibcomms.agency/releases24/reithera-wishes-to-issue-a-correction-in-its-release 2024-12-11 https://www.ibcomms.agency/releases24/exmoor-and-virica-receive-funding-to-improve-aav-gene-therapy-manufacturing 2024-12-11 https://www.ibcomms.agency/releases24/germfree-launches-smarthood%E2%84%A2%3A-a-groundbreaking%2C-software-agnostic-iv-workflow-solution-transforming-sterile-compounding 2024-12-11 https://www.ibcomms.agency/releases24/75%25-of-hospitals-face-medication-shortages-%E2%80%93-germfree-and-on-demand-pharmaceuticals-partner-to-deliver-localized-production-solutions 2024-12-11 https://www.ibcomms.agency/releases24/patients%2C-scientists-agree%3A-automated-red-blood-cell-exchange-enhances-quality-of-life-in-sickle-cell-disease-patients 2024-12-11 https://www.ibcomms.agency/releases24/germfree-acquires-arcoplast-to-expand-turnkey-facility-solutions-and-expand-market-reach-through-superior-architectural-finishes 2024-12-11 https://www.ibcomms.agency/releases24/quell-therapeutics-expands-manufacturing-capabilities-for-car-treg-cell-therapy-pipeline-through-partnership-with-exmoor-pharma 2024-12-11 https://www.ibcomms.agency/releases24/%C2%A0scaleready-announces-a-g-rex%C2%AE-grant-has-been-awarded-to-immunoscape 2024-09-23 https://www.ibcomms.agency/releases24/scaleready-announces-a-g-rex%C2%AE-grant-has-been-awarded-to-verismo-therapeutics 2024-09-23 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-collaborates-with-nova-biomedical-to-bring-automated-cell-culture-sensing-to-quantum-flex%E2%80%A8 2024-09-23 https://www.ibcomms.agency/releases24/anthony-nolan-to-open-stem-cell-collection-centre-to-help-patients-and-enable%C2%A0cell-and-gene-therapy-research%C2%A0 2024-09-17 https://www.ibcomms.agency/releases24/organabio-expands-cell-and-gene-therapy-donor-base-to-include-patients-with-lupus%2C-other-autoimmune-diseases 2024-09-17 https://www.ibcomms.agency/releases24/kosten-digital-launches-in-the-u.s.-to-transform-life-sciences-with-custom-ai-solutions%2C-welcomes-industry-leader-amy-duross-to-advisory-board 2024-09-17 https://www.ibcomms.agency/releases24/cellprothera-shares-u.s.-regulatory-progress-of-protheracytes%C2%AE-cell-therapy-program- 2024-09-04 https://www.ibcomms.agency/releases24/scaleready-announces-the-inaugural-g-rex%C2%AE-grant-has-been-awarded-to-stanford-medicine-laboratory-for-cell-and-gene-medicine 2024-09-04 https://www.ibcomms.agency/releases24/germfree-and-caring-cross-partner-to-transform-access-to-cellular-gene-therapies%C2%A0 2024-09-17 https://www.ibcomms.agency/releases24/cellprothera-announces-positive-phase-i%2Fiib-data-for-protheracytes%C2%AE-cell-therapy-in-acute-myocardial-infarction 2024-09-17 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-adds-mani-venkatesh-to-executive-team-as-vp-of-digital-transformation 2024-09-17 https://www.ibcomms.agency/releases24/scaleready-announces-%2420-million-g-rex%C2%AE-grant-program-for-the-advancement-of-cell-and-gene-therapy-(cgt)-development-and-manufacturing 2024-09-17 https://www.ibcomms.agency/releases24/likarda-and-cold-chain-technologies-announce-exclusive-partnership-to-revolutionize-cell-therapy-material-transportation-and-storage 2024-09-17 https://www.ibcomms.agency/releases24/imm-joins-the-magic-consortium-to-advance-research-on-muscular-dystrophies 2024-12-11 https://www.ibcomms.agency/releases24/leriglitazone-halts-disease-progression-in-adult-patients-with-early-cerebral-adrenoleukodystrophy-in-compassionate-use-study-published-in-brain 2024-09-17 https://www.ibcomms.agency/releases24/cellprothera-and-biocardia-collaborate-on-successful-phase-ii-trial-of-protheracytes%E2%84%A2-for-the-treatment-of-acute-myocardial-infarction 2024-09-17 https://www.ibcomms.agency/releases24/exmoor-pharma's-gmp-cell-and-gene-therapy-manufacturing-facility-receives-license-from-mhra%C2%A0 2024-09-17 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-and-charles-river-demonstrate-versatility-of-finia-automated-cell-and-gene-therapy-fill-and-finish-platform 2024-09-17 https://www.ibcomms.agency/releases24/organabio-manufactures-first-gmp-cryopreserved-leukopaks-for-two-new-biopharma-partners%E2%80%99-allogeneic-cell-therapies 2024-09-17 https://www.ibcomms.agency/releases24/organabio-expands-california-cpc-services-hub-for-sample-processing-and-cryopreservation-capabilities-to-support-big-pharma-clinical-trials 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-provides-further-information-on-its-restructuring-plan%C2%A0 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-and-its-restructuring-practitioner-(me-yves-brulard)-submit-a-global-restructuring-plan-covering-the-years-2024-2030-to-the-enterprise-court-of-nivelles 2024-09-17 https://www.ibcomms.agency/releases24/germfree-and-orgenesis-announce-asset-purchase-and-strategic-partnership-intended-to-revolutionize-cell-and-gene-therapy-through-decentralized-production-and-global-accessibility 2024-09-17 https://www.ibcomms.agency/releases24/likarda-appoints-shelly-adams-as-chief-commercial-officer 2024-04-17 https://www.ibcomms.agency/releases24/green-elephant-biotech-expands-sustainable-96-well-plate-line-for-light-sensitive-experiments 2024-09-17 https://www.ibcomms.agency/releases24/organabio-launches-on-demand-gmp-compliant-hematopoietic-stem-cell-source-for-advanced-therapy-manufacturing 2024-09-17 https://www.ibcomms.agency/releases24/information-on-the-total-number-of-voting-rights-and-shares 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-presents-successful-preclinical-data-on-its-ato-medication-for-controlling-key-symptoms-at-the-2024-systemic-sclerosis-world-congress 2024-09-17 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-partners-with-cira-foundation-to-develop-automated-ips-cell-manufacturing 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-releases-details-of-optimized-administration-approach-ahead-of-planned-phase-3-trial-of-oato-for-chronic-graft-versus-host-disease 2024-09-17 https://www.ibcomms.agency/releases24/biocentriq(r)-presents-first-public-car-t-expansion-data-from-terumo-blood-and-cell-technologies%E2%80%99-quantum-flex-cell-expansion-system 2024-09-17 https://www.ibcomms.agency/releases24/information-on-the-total-number-of-voting-rights-and-shares 2024-09-17 https://www.ibcomms.agency/releases24/erratum%3A-trakcel-to-expand-largest-commercial-cgt-integrated-partner-network-to-meet-industry%E2%80%99s-growing-needs 2024-09-17 https://www.ibcomms.agency/releases24/cellprothera-collaborates-with-japanese-stem-cell-experts-at-shonan-kamakura-general-hospital-(skgh)-on-clinical-manufacturing-for-upcoming-autologous-stem-cell-trials-in-ischemic-diseases 2024-09-17 https://www.ibcomms.agency/releases24/hundreds-of-sickle-cell-patients-are-to-benefit-from-%C2%A31.5m%C2%A0technology-investment-from-nhs-england 2024-09-17 https://www.ibcomms.agency/releases24/terumo-blood-and-cell-technologies-sponsored-panel-publishes-first-of-its-kind-international-consensus-recommendations-for-pregnancy-complications-in-patients-with-sickle-cell-disease 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-raises-%E2%82%AC********--in-private-placement-of-new-shares-with-established-new-investors 2024-09-17 https://www.ibcomms.agency/releases24/green-elephant-biotech-launches-the-world's-first-plant-based-96-well-plate%2C-for-laboratory-sustainability 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-patent-granted-in-canada-for-broader-protection-of-ato-therapeutic-platfor 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-presents-new-phase-3-data-on-jta-004-to-treat-severe-osteoarthritis-pain-at-the-2024-oarsi-world-congress 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-files-for-additional-patent-protection-following-new-clinical-evidence-of-efficacy-for-jta-004-in-osteoarthritis 2024-09-17 https://www.ibcomms.agency/releases24/trakcel-launches-consultancy-services-to-share-extensive-cell-and-gene-therapy-process-development-expertise 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-provides-support-to-forthcoming-european-conference-on-graft-versus-host-disease. 2024-01-31 https://www.ibcomms.agency/releases24/organabio-named-translation-award-finalist-for-supporting-car-nkt-cell-therapies-into-clinical-trials 2024-09-17 https://www.ibcomms.agency/releases24/cellquest-launches-early-access-program-with-first-cosynest-automated-car-t-manufacturing-partner 2024-01-30 https://www.ibcomms.agency/releases24/biosenic-reaches-agreement-on-a-binding-term-sheet-with-phebra-pty-ltd.-with-respect-to-the-development-of-the-first-oral-formulation-of-arsenic-troxide-for-cgvhd-treatment 2024-09-17 https://www.ibcomms.agency/releases24/biosenic-appoints-dr-carole-nicco-as-chief-operating-officer-in-addition-to-chief-scientific-officer 2024-01-30 https://www.ibcomms.agency/releases24/biosenic-signs-a-new-subscription-agreement-for-a-maximum-of-eur-1.2m-in-convertible-bonds 2024-01-30